Marshall Wace LLP Takes $331,000 Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Marshall Wace LLP acquired a new position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 2,425 shares of the company's stock, valued at approximately $331,000.

Other institutional investors have also bought and sold shares of the company. Golden State Wealth Management LLC purchased a new stake in Neurocrine Biosciences in the 4th quarter worth $25,000. Huntington National Bank raised its position in shares of Neurocrine Biosciences by 73.5% in the 4th quarter. Huntington National Bank now owns 229 shares of the company's stock worth $31,000 after acquiring an additional 97 shares in the last quarter. Brooklyn Investment Group raised its stake in shares of Neurocrine Biosciences by 99.1% during the 4th quarter. Brooklyn Investment Group now owns 231 shares of the company's stock worth $32,000 after acquiring an additional 115 shares in the last quarter. Lindbrook Capital LLC boosted its stake in Neurocrine Biosciences by 53.5% in the fourth quarter. Lindbrook Capital LLC now owns 373 shares of the company's stock valued at $51,000 after acquiring an additional 130 shares in the last quarter. Finally, R Squared Ltd acquired a new stake in shares of Neurocrine Biosciences in the 4th quarter worth $61,000. Hedge funds and other institutional investors own 92.59% of the company's stock.

Insider Buying and Selling

In other Neurocrine Biosciences news, Director William H. Rastetter sold 30,000 shares of the business's stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $110.20, for a total transaction of $3,306,000.00. Following the completion of the sale, the director now directly owns 37,491 shares of the company's stock, valued at approximately $4,131,508.20. The trade was a 44.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Julie Cooke sold 700 shares of the business's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $118.28, for a total transaction of $82,796.00. Following the transaction, the insider now owns 18,831 shares in the company, valued at approximately $2,227,330.68. This trade represents a 3.58 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 43,907 shares of company stock valued at $4,935,982 over the last quarter. Insiders own 4.30% of the company's stock.

Analysts Set New Price Targets

Several brokerages have commented on NBIX. Royal Bank of Canada lifted their price objective on shares of Neurocrine Biosciences from $137.00 to $145.00 and gave the company an "outperform" rating in a research note on Tuesday. Morgan Stanley reaffirmed an "overweight" rating and issued a $150.00 target price (down previously from $185.00) on shares of Neurocrine Biosciences in a research report on Friday, March 7th. Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $158.00 to $160.00 and gave the company a "buy" rating in a research report on Tuesday. BMO Capital Markets increased their target price on shares of Neurocrine Biosciences from $96.00 to $115.00 and gave the company a "market perform" rating in a research report on Tuesday. Finally, Evercore ISI reduced their target price on shares of Neurocrine Biosciences from $190.00 to $185.00 and set an "outperform" rating for the company in a research note on Thursday, April 24th. Three analysts have rated the stock with a hold rating and twenty have given a buy rating to the company's stock. Based on data from MarketBeat.com, Neurocrine Biosciences has an average rating of "Moderate Buy" and an average price target of $162.00.

Neurocrine Biosciences Trading Down 3.4 %

Shares of NASDAQ:NBIX traded down $4.09 during trading on Thursday, hitting $117.52. 2,428,423 shares of the company were exchanged, compared to its average volume of 1,108,546. The stock has a market cap of $11.63 billion, a price-to-earnings ratio of 35.72, a P/E/G ratio of 0.77 and a beta of 0.26. The firm has a fifty day moving average price of $106.12 and a two-hundred day moving average price of $121.80. Neurocrine Biosciences, Inc. has a fifty-two week low of $84.23 and a fifty-two week high of $157.98.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.70 by ($0.62). Neurocrine Biosciences had a net margin of 14.49% and a return on equity of 13.38%. The business had revenue of $572.60 million during the quarter, compared to the consensus estimate of $587.06 million. During the same period in the previous year, the firm posted $1.20 EPS. The company's revenue was up 11.1% compared to the same quarter last year. As a group, research analysts predict that Neurocrine Biosciences, Inc. will post 4.28 EPS for the current year.

Neurocrine Biosciences declared that its Board of Directors has initiated a share buyback plan on Friday, February 21st that authorizes the company to buyback $500.00 million in outstanding shares. This buyback authorization authorizes the company to repurchase up to 4.2% of its shares through open market purchases. Shares buyback plans are usually a sign that the company's management believes its shares are undervalued.

Neurocrine Biosciences Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.